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Brain metastases from lung cancer and radiosurgery: 6 
years follow up comparing the RPA, SIR and BSBM patients 
stratification systems
Daniel, Devriendt1 Paul, Van Houtte1 Françoise, Desmedt1 Nicolas, 
Massager2 Marc, Levivier2 Jacques, Brotchi2 
1 Institut Jules Bordet, Brussels, Belgium 2 Gamma Knife Center of 
ULB, Hopital Erasme, Brussels, Belgium 
Objective: to compare three stratiﬁcation systems, the recursive parti-
tioning analysis (RPA), the score index for radiosurgery (SIR) and the 
basic score for brain metastases (BSBM) with a 6 years follow up for 
patients with brain metastases (BM) from lung cancer and treated by 
radiosurgery.
Material and Methods: between February 2000 and December 2005, 
117 patients with 275 brain metastases were treated with a Leksell 
Gamma Knife model C. Median marginal dose was 20 Gy at a median 
50 % isodose. 
Results: median survival (MS) for the entire population is 12 months. 
The survival rate is respectively 50, 33, 12, 10 and 5 % at 1, 2, 3, 4 and 
more than 5 years follow up. Univariate analysis conﬁrms the predic-
tive value of the three systems. MS is 22 months for RPA class I, 12 
months for RPA class II and 2 months for RPA class III, (p < 0,0001). 
According to SIR system, MS is 21, 12, 6 and 3 months for scores 8 to 
10, 5 to 7, 4 and 0 to 3 respectively, (p < 0,0001). According to BSBM 
system, MS is 23, 8, 6 and 2 months for scores 3, 2, 1 and 0 points 
respectively (p < 0,0001).
Conclusions: this comparative study conﬁrms the usefulness of all 
three systems of classiﬁcation to predict the outcome of patients treated 
by radiosurgery. Patients who will beneﬁt the most from RS belong the 
groups RPA class I-II, SIR 5-10 and BSBM 2-3. Patients with BSBM 
score 0, SIR score 0 to 3 and RPA class III have a MS around 3 months 
and are not likely to beneﬁt from radiosurgery.
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Prediction of radiation pneumonitis by dose-volume histogram 
parameters, especially focused on main bronchus
Ebara, Takeshi; Kawamura, Hidemasa; Ishikawa, Hitoshi;  
Nonaka, Tetsuo; Kiyohara, Hiroki; Wakatsuki, Masaru; Sakurai, 
Hideyuki; Nakano, Takashi 
Dept. of Radiation Oncology, Gunma University Graduate School of 
Medicine, Maebashi, Japan
Background: Recently the risk of radiation pneumonitis (RP) devel-
oping after thoracic irradiation has been reported to depend on the 
irradiated normal lung volume. Although the hilar region has been 
considered to play a key role in developing PR, there is no report about 
dosimetric analysis of the hilar region. Hence, we tried to evaluate 
dosimetric parameters of not only the normal lung tissue but also the 
hilar region. However, because it was difﬁcult to contour the hilar 
region precisely, each main bronchus was employed in stead of the 
hilar region.
Methods: Forty two patients treated with radiation for thoracic ma-
lignancy (lung cancer; 35 patients and mediastinum tumor; 7 patients) 
were retrospectively analyzed. RP was graded according to Common 
Terminology Criteria for Adverse Events version 3.0. Pneumonitic 
event that was not due to infection (proven by blood or respiratory cul-
ture) or tumor progression was scored as radiation pneumonitis within 
3 months after the completion of radiotherapy. Univariate analyses was 
performed the following dosimetric factors generated from the dose-
volume histogram (DVH); mean lung dose (MLD), relative volumes 
of lung receiving more than a threshold dose (Vdose). Each main 
bronchus was deﬁned that the ipsilateral main bronchus was on the side 
containing more than 50% of the PTV and the other main bronchus was 
the contralateral. Mean bronchial dose (MBD) and relative volumes of 
bronchus receiving more than a threshold dose (BrVdose) were gener-
ated from the DVH. Also, potential predictive clinical factors examined 
included age, performance status, chemotherapy, chronic obstructive 
pulmonary disease (COPD), lactate dehydrogenase (LDH), diabetes 
mellitus (DM), hypertension, and Brinkman Index.
Results: Radiotherapy was delivered at 2.0 Gy fractions once daily to a 
total of 34-70 Gy (median 60) with a median follow-up of 7.9 months. 
Of them, 16 patients were received concurrent chemotherapy includ-
ing platinum agents. Grade of 0, 1, 2, 3, and 5 RP was observed in 12, 
15, 11, 3 and 1 patients, respectively. V25 was marginally signiﬁcant 
(p=0.07). On the other hand, ipsilateral BrV15, 20, 25, 30, 60 and 
MBD and contralateral BrV60 were signiﬁcantly associated with the 
development of grade 2 or worse RP (p<0.05). Among them, ipilateral 
BrV60 was most signiﬁcant (p=0.0012). There is no signiﬁcant factor 
among the clinical factors.
Conclusions: The bronchial dosimetric parameters, especially high 
dose, were more useful predictive factors than normal lung tissue dosi-
metric parameters for RP.
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Prognostic factors for patients with advanced and metastatic non 
small cell lung cancer (NSCLC): classical factors= performans 
status (PS), gender and extension of disease; new factors= 
expression of EGFR, p53 and cell proliferation defined by Ki67
Gamaz, Malika1 Bouzid, Kamel2 Baba-Ahmed, Rebiha3 Taright, Samia4 
Amrane, Rabah4 Hannoun, Djoher5 
1 Medical Oncology Center CPMC, Algiers, Algeria 2 Medical Oncol-
ogy Center, Algiers, Algeria 3 Department of Pathology, Algiers, Algeria 
4 Department of Pneumology, Algiers, Algeria 5 National Institut of 
Public Health, Algiers, Algeria 
The aim of the study was to assess the relation between new factors 
prognostic (expression of EGFR, p53, cell proliferation deﬁned by the 
monoclonal antibody Ki67); classical factors prognostic (performans 
status PS, age, gender, extension of the disease) and survival of patients 
with non-small cell lung cancer stage III and IV.
Patient and Methods: 80 patients were included in this study (male 72 / 
female 8); the median follow up was 15 months.
All tumor samples were formalin-ﬁxed and parafﬁn-embedded. The 
expression of p53, EGFR and Ki 67 were assessed with the use of im-
munohistochemically (IHC). P53 was assessed in 66 cases, EGFR in 73 
cases and cell proliferation deﬁned by the monoclonal antibody Ki67 in 
63 cases. 
Results: The expression of p53 was positive in 20 % of cases, EGFR 
was positive in 58,7 % of cases and cell proliferation in 40 % of cases.
Survival was estimated from the date of ﬁrst cycle of chemotherapy 
using median survival and the Kaplan-Meier survival analysis method. 
for each factor.
